Dr. Ahmed Hassan AbdelAziz sharing new milestones for Breast Cancer patients

1-One of the most significant results in metastatic HR+ breast cancer in this ESMO was the phase 3 RCT evERA:

Combining Next generation oral SERD ( girdestrant) with Everolimus significantly improved progression free survival vs Everolimus plus any other endocrine partner ( Tam/ AI/ FV)

Benefit was seen irrespective of ESR1m status

2-Another very simple design study but practice changing was the

Timing of Pegfilgrastim Administration and Taxane- and Pegfilgrastim-Induced Bone Pain:

A Prospective, Randomized Phase 3 Trial

The results suggest that administering pegfilgrastim 72 hours after chemotherapy

significantly reduced bone pain compared with 24 and 48 hours, without compromising prophylactic efficacy.

3-VIKTORIA trial : Gedatolisilib + Palbo +FV vs Geda + FV vs FV in the PIK3CA WT

This is the first study to demonstrate marked improvement in PFS in by blocking the PIK3CA / AKT / mTOR pathway in PIK3CA WT disease after prior CDK4/6 I

HR = 0.24 ( PFS 9.3 m vs 7.4m )

Another potentially practice changing trial